世衛:輝瑞(PFE.US)Paxlovid新冠口服藥適用於高風險患者
世衛表示,強烈推薦輝瑞(PFE.US)對抗新冠病毒口服藥Paxlovid予住院風險最高的輕度和中度新冠病患,如未接種疫苗、年齡較大或免疫功能低的患者,認爲是迄今爲止對高危患者的最佳治療選擇。惟不建議用於風險較低的患者,因發現對低風險患者好處太少。
該建議基於兩項涉及3,078名患者的隨機對照試驗數據,顯示經過有關治療後,患者住院風險降低85%。意味着在高風險組別(住院風險超過10%),每1,000名患者的住院人數減少84人。
不過,世衛認爲對中、低收入國家而言,要獲得Paxlovid存在難度。另由於Paxlovid對治療染疫的早期階段更有效,但中、低收入國家的檢測能力有限,難確保患者能在感染早期被發現。
世衛又呼籲輝瑞對Paxlovid定價及交易更透明化,擴大其藥品專利許可的地理範圍,以便更多仿製藥製造商可開始生產該藥物,並以可承受的價格更快地提供有關藥物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.